CJC-1295 + IpamorelinvsNAD+

The CJC-1295 + Ipamorelin combination exploits the synergistic interaction between two distinct signaling pathways on pituitary somatotroph cells. CJC-1295 (Mod GRF 1-29) activates the GHRH receptor, a Gs-coupled GPCR that stimulates adenylyl cyclase, raising intracellular cAMP and activating PKA. Ipamorelin activates the ghrelin/GHS-R1a receptor, a Gq/11-coupled GPCR that stimulates phospholipase C, generating IP3 and DAG, raising intracellular calcium and activating protein kinase C.

These two pathways converge on the final common pathway of GH vesicle exocytosis but through complementary mechanisms. cAMP/PKA signaling (from CJC-1295) primes GH gene transcription and vesicle loading, while calcium/PKC signaling (from Ipamorelin) triggers the actual calcium-dependent exocytosis of GH-containing secretory granules. When both pathways are activated simultaneously, the resulting GH pulse is significantly larger than what either peptide produces alone — studies suggest the combined GH output can be 3-5 times greater than either agent in isolation.

Additionally, Ipamorelin's hypothalamic effects complement CJC-1295's direct pituitary action. At the hypothalamic level, ghrelin receptor agonists suppress somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This creates a permissive window during which CJC-1295's GHRH-like stimulation of somatotrophs is maximally effective. Importantly, both peptides preserve the natural pulsatile pattern of GH release — somatostatin feedback still operates between pulses, maintaining the physiological pulse spacing that is important for target tissue sensitivity. The combination's selectivity profile is also favorable: Ipamorelin's selectivity avoids the cortisol and prolactin elevation seen with older GHRPs, while CJC-1295's 30-minute half-life avoids the sustained GH elevation of the DAC version. This makes CJC/Ipa the most widely prescribed GH peptide stack in anti-aging medicine.

Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme consisting of nicotinamide mononucleotide (NMN) joined to adenosine monophosphate (AMP) through a pyrophosphate bond. It exists in oxidized (NAD+) and reduced (NADH) forms and participates in over 500 enzymatic reactions, making it one of the most central molecules in cellular metabolism.

As a redox cofactor, NAD+ accepts hydride ions (H-) during catabolic reactions. In glycolysis, the TCA cycle, and fatty acid beta-oxidation, NAD+ is reduced to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP production. Without adequate NAD+, the entire energy production machinery of the cell grinds to a halt.

Equally important are NAD+'s roles as a consumed substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases and ADP-ribosyltransferases that use NAD+ as a co-substrate, cleaving it to nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 and SIRT3 are particularly important for aging — SIRT1 deacetylates PGC-1α (activating mitochondrial biogenesis), FOXO transcription factors (activating stress resistance), and NF-κB (suppressing inflammation). SIRT3 in the mitochondrial matrix activates SOD2 and other mitochondrial enzymes. PARPs (poly-ADP-ribose polymerases) consume NAD+ during DNA damage repair, adding chains of ADP-ribose to histones near DNA breaks to recruit repair machinery. CD38, an NAD+-consuming glycohydrolase on immune cells, regulates calcium signaling and immune activation.

NAD+ levels decline 40-60% between ages 40 and 70, driven by increased CD38 expression (with chronic low-grade inflammation), increased PARP activity (from accumulated DNA damage), and reduced synthesis (decreased NAMPT enzyme activity). This decline impairs sirtuin function, reduces ATP production, compromises DNA repair, and contributes to virtually every hallmark of aging. Supplementation strategies aim to restore NAD+ levels either directly (IV infusion) or through biosynthetic precursors: NMN enters the salvage pathway one step from NAD+, while NR (nicotinamide riboside) requires an additional phosphorylation step.